Brief: Daewoong Pharmaceutical Announces U.S. FDA Clearance Of IND Application For DWP213388, First-In-Class Irreversible Oral Dual Acting Inhibitor For Autoimmune Diseases
15/08/2022 14:15
Aug 15 (Reuters) - Daewoong Pharma 069620.KS :
* DAEWOONG PHARMACEUTICAL ANNOUNCES US FDA CLEARANCE OF IND
APPLICATION FOR DWP213388, FIRST-IN-CLASS IRREVERSIBLE ORAL DUAL
ACTING INHIBITOR FOR AUTOIMMUNE DISEASES
Source text for Eikon: ID:nPn7PC8jFa
Further company coverage: 069620.KS
Recent news on Daewoong Pharma
See all newsBrief: Daewoong Pharma Q2 Operating. Profit 77 Billion Won, Up 23% Y/Y
Brief: Daewoong Pharma Wins 92.6 Billion Won Order
Brief: Daewoong Pharma Q4 Operating Profit 45.5 Billion Won, Up 9% From Year Earlier
Brief: Daewoong Pharma Q2 Operating Profit 62.5 Billion Won, Up 26% From Year Earlier
Brief: Daewoong Pharma Q1 Operating Profit 42 Billion Won, Up 34.5% From Year Earlier